

Alovudine



Alovudine, also known as FLT and MIV-310, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs work by blocking reverse transcriptase, a protein that HIV needs to make more copies of itself.

HIV/AIDS-Related Uses

Alovudine is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. Alovudine is similar to zidovudine (AZT) and may be effective against HIV strains that have developed resistance to AZT.

Alovudine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Information

Alovudine comes in a liquid form and is taken orally.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, alovudine can cause some unwanted effects. While not all of these effects are known, serious bone marrow suppression has been reported in patients taking alovudine. When the bone marrow is suppressed, new red and white blood cells are not produced; a patient becomes anemic and is at increased risk of infection. Individuals should tell a doctor if they have symptoms of any side effects.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve Alovudine, visit the ClinicalTrials.gov web site at

<http://www.clinicaltrials.gov>. In the Search box, enter: Alovudine AND HIV Infections.

Manufacturer Information

Alovudine
Boehringer Ingelheim GmbH
55216 Ingelheim am Rhein
Germany

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET